Abstract: Objective To observe the therapeutic effect of compound fetal bovine liver extract in patients with nonalcoholic steatohepatitis （NAFLD）. Methods 120 patients with nonalcoholic steatohepatitis were recruited in our hospital between January 2014 and January 2016,and the patients with NAFLD were randomly divided into study and control group with 60 cases in each. All patients were given the same dietary guidelines to reduce calorie and fat intake,and daily exercise was also instructed. Patients in the control group received nothing that might have impact on lipid metabolism or liver function,while patients in the study group were given compound fetal bovine liver extract tablets for three months. Liver function,blood lipids,liver fibrosis index and Fibroscan score（CAP value） before and after treatments were obtained. Results After the end of three month treatment,serum AST,ALT and GGT levels in study group were significantly lower than those in patients in control group [（38.53±10.56） U/L vs. （48.83±9.46） U//L,（42.35±12.04） U//L vs. （57.92±13.84） U//L and （44.99±8.74） U//L vs. （50.35±9.84） U//L, respectively,P<0.05 for all];Patients in study group also had lower blood TG and HDL-C levels than those in patients in control group after the treatment [（4.41±1.12） mmol/L vs. （5.20± 0.79） mmol/L, （0.87±0.17） mmol/L vs. （0.74±0.11） mmol/L,respectively,P<0.05 for both];The level of serum HA,LN,PC Ⅲ,and C-Ⅳ levels in patients in study group were remarkably lower than those in the controls after the treatment [（70.18± 20.57） μg/L vs. （82.18±21.53） μg/L,（126.84±27.15） μg/L vs. （133.19±26.68） μg/L,（113.84+25.68） μg/L vs. （128.85±26.35） μg/L,and（61.96±9.46） μg/L vs. （67.94±10.75） μg/L,respectively,P<0.05 for all]; Compared with patients in control group,hepatic CAP values in patients in study group declined more obvious after the treatment （P<0.05）. Conclusion Compound fetal bovine liver extract can improve liver function, blood lipids and liver fibrosis index in patients with nonalcoholic fatty hepatitis.

Key words: Nonalcoholic steatohepatitis, Compound fetal bovine liver extract, Blood lipids, Efficacy